AI-guided life sciences intelligence for better BD&L decisions

LSX Investival Showcase London brings together biotech innovators, medtech pioneers, healthcare investors and corporate strategics from across Europe and beyond, creating a dynamic environment for investment discussions, partnering opportunities and business development. For life science companies, the Investival Showcase offers a valuable opportunity to build visibility with the European and global market, pitch to active investors and build new connections through organised partnering and networking opportunities. Taking place on the first day of London Life Science Week, it's growing in size and scale. It's the first and biggest public event of the week, open to the wider life science community, and offers full partnering facilities to all attendees. Get a 15% discount to LSX Investival Showcase Europe by using the promo code: VENTUREVALUATION15.

Delegates from Venture Valuation and Biotechgate will attend the event.

AutomaPlus 2026 (Zurich, 16-17 November) focuses on digital instruments for the pharma industry. The agenda covers AI, Pharma 4.0, digital factories and GxP-ready solutions, with participants from GSK, Takeda, Novartis, WHO, Emerson and others.

The Creative Disruption Forum is a high-level, interactive gathering built for executive leaders, senior researchers, startup founders, and biotech investors. The Quantum Horizon Meets Real-World Science We are witnessing a transformative shift in health innovation. While emerging paradigms like quantum computing promise to fundamentally redefine how we process biological complexity in the future, biopharma leaders today need actionable, deployable technologies to de-risk pipelines, accelerate drug discovery, and improve clinical outcomes now. The Latest & Future Technologies Impacting Health Innovation and Life Sciences bridges the gap between tomorrow’s deep-tech horizons and today’s high-impact biological and computational breakthroughs. Hosted at ARC West London as a flagship London Life Sciences Week event, this interactive forum brings together biopharma executives, tech bio founders, investors, and academic leaders for unscripted, Chatham House Rules discussions on what is genuinely working, where the bottlenecks lie, and how to build scalable healthcare solutions. From physical molecule-to-protein target engagement (such as CETSA® platforms) and human-relevant New Approach Methodologies (NAMs) to real-world AI applications in lead optimization, this event delivers an unfiltered "boots on the ground" look at modern translational science.

A thought leadership workshop for Business & Research Leaders from life sciences innovation companies and investors Are you a business leader of a Life Science Innovation company or investor? Are you interested in discussing current dealmaking and investment strategies that are working? Do want to learn more about other people's experiences, or share your thoughts and queries around investment & dealmaking? Are you looking to learn from, and meet with, your peers and experienced industry professionals and seasoned investors? What are the Dealmaking & Investment Strategies that are working? The life sciences and biotech sector is currently grappling with a range of investment challenges shaped by regulatory pressures, evolving market dynamics, and shifting public sentiment. As the industry strives to recover from the pandemic’s disruption, deal-making has become more cautious and complex, reflecting the demand for robust compliance and transparency. One significant challenge is the increased regulatory scrutiny following COVID-19. Investors are now prioritizing companies with clear pathways to regulatory approval and validated clinical data. This trend influences venture capital flows, as investors seek to minimize risk by backing firms with established compliance measures. Smaller biotech companies, in particular, face hurdles in securing funding, as they often lack the resources to navigate the intricate regulatory landscape effectively. Moreover, public perception regarding drug pricing and access is steering investment decisions. Investors are more inclined to support companies that align their missions with social responsibility and ethical practices. This societal lens encourages firms to develop narratives that emphasize not only financial viability but also positive community impact, a factor that is increasingly crucial in attracting committed investors. To address these challenges, strategic partnerships are emerging as a vital solution. Collaborations between small biotech startups and larger pharmaceutical firms can enhance credibility and access to resources, providing a safety net for navigating regulatory complexities. Additionally, the use of non-dilutive funding—such as grants and government contracts—has gained traction, allowing companies to focus on long-term innovations without immediate financial pressures.In this evolving landscape, investment strategies that embrace transparency, collaboration, and ethical considerations will be pivotal. As the life sciences sector adapts, innovative approaches will unlock new opportunities for growth, ensuring a sustainable path forward for the future of healthcare. Green-Shoots? We will explore what is happening in Europe and the US with experts that know the activity in the financial marketplace. We will have Bill Hicks with us from Mintz in Boston, US along with James Fry from Mills & Reeve who has his finger on the pulse regarding the UK and EU markets, along with other experts.